Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
Switch from single-tablet regimen to 3 tablets works in Denmark

Switching from an efavirenz-containing single-tablet regimen (STR) to an efavirenz containing triple-tablet regimen (TTR) to save money maintained viral suppression in Denmark. Antiretroviral-naive people who started the TTR attained the same virologic suppression rate as people who started the STR combination.

Published
10 July 2014
From
International AIDS Society
New ARV prescribing guidelines for London (2014)

The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.

Published
01 July 2014
From
HIV i-Base
Viral load rebounds in 35% of people using PI/r monotherapy: results of five-year PIVOT study

A long-term strategy study sponsored by the Medical Research Council (MRC) in the UK reported low rates of serious complications and the potential to reduce drug costs. However, more than a third of people on the PI/r monotherapy group had viral load rebound compared to only 3% of people on standard combination therapy.

Published
10 March 2014
From
HIV i-Base
U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union.

Published
16 December 2013
From
Gilead press release
Once-daily raltegravir for 48 weeks as maintenance therapy in Paris

Sixty-eight of 71 people who switched to once-daily raltegravir with a viral load below 50 copies maintained virologic suppression for 48 weeks in an observational study at a Paris hospital. Virologic failure occurred in 3 people taking nucleos(t)ides with raltegravir who had a previous nucleos(t)ide failure.

Published
22 October 2013
From
NATAP
TDF/FTC-to-ABC/3TC switch maintains viral suppression, eases bone markers

A switch from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine (ABC/3TC), both with atazanavir/ritonavir, maintained viral suppression through 48 weeks in a noninferiority analysis and improved bone and kidney markers. Four people in the ABC/3TC arm (2%) and one in the TDF/FTC arm (1%) had study-defined virologic failure by week 48.

Published
19 September 2013
From
NATAP
Switching From Efavirenz to Rilpivirine Combo Quells CNS Side Effects

Swapping efavirenz-containing Atripla for rilpivirine-containing Complera (Eviplera in Europe) significantly lowered rates of central nervous system (CNS) side effects and sleep disturbances in a 40-person multicenter pilot trial.

Published
13 September 2013
From
NATAP
Lessons Learned When the Labs Go Awry

David Fawcett describes the feelings - and the lessons - when a rebound in viral load resulted in a change of his HIV medication.

Published
10 September 2013
From
TheBody.com
Computer models predict how patients will respond to HIV drugs

Results of a new study demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. Crucially for patients in poorer countries, the models do not require the results of expensive drug resistance tests to make their predictions. The study also showed that the models were able to identify alternative drug combinations that were predicted to work in cases where the treatment used in the clinic had failed, suggesting that their use could avoid treatment failure.

Published
14 March 2013
From
Eurekalert Inf Dis
PI monotherapy for HIV — an idea whose time has passed?

Patients who switched from suppressive triple-drug therapy to boosted protease-inhibitor monotherapy had unreasonably high rates of treatment failure.

Published
05 December 2012
From
Journal Watch

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.